INMB
Price
$7.30
Change
-$0.16 (-2.14%)
Updated
May 23 closing price
Capitalization
169.44M
67 days until earnings call
MDWD
Price
$20.37
Change
+$0.03 (+0.15%)
Updated
May 23 closing price
Capitalization
220.15M
80 days until earnings call
Interact to see
Advertisement

INMB vs MDWD

Header iconINMB vs MDWD Comparison
Open Charts INMB vs MDWDBanner chart's image
INmune Bio
Price$7.30
Change-$0.16 (-2.14%)
Volume$305.82K
Capitalization169.44M
MediWound
Price$20.37
Change+$0.03 (+0.15%)
Volume$44.1K
Capitalization220.15M
INMB vs MDWD Comparison Chart
Loading...
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
INMB vs. MDWD commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INMB is a Hold and MDWD is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (INMB: $7.30 vs. MDWD: $20.37)
Brand notoriety: INMB and MDWD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: INMB: 118% vs. MDWD: 55%
Market capitalization -- INMB: $169.44M vs. MDWD: $220.15M
INMB [@Biotechnology] is valued at $169.44M. MDWD’s [@Biotechnology] market capitalization is $220.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INMB’s FA Score shows that 0 FA rating(s) are green whileMDWD’s FA Score has 1 green FA rating(s).

  • INMB’s FA Score: 0 green, 5 red.
  • MDWD’s FA Score: 1 green, 4 red.
According to our system of comparison, MDWD is a better buy in the long-term than INMB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INMB’s TA Score shows that 3 TA indicator(s) are bullish while MDWD’s TA Score has 6 bullish TA indicator(s).

  • INMB’s TA Score: 3 bullish, 5 bearish.
  • MDWD’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MDWD is a better buy in the short-term than INMB.

Price Growth

INMB (@Biotechnology) experienced а -7.12% price change this week, while MDWD (@Biotechnology) price change was -0.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

INMB is expected to report earnings on Jul 30, 2025.

MDWD is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDWD($220M) has a higher market cap than INMB($169M). INMB YTD gains are higher at: 56.317 vs. MDWD (14.438). MDWD has higher annual earnings (EBITDA): -6.58M vs. INMB (-41.52M). MDWD has more cash in the bank: 45.6M vs. INMB (19.3M). INMB has less debt than MDWD: INMB (347K) vs MDWD (6.46M). MDWD has higher revenues than INMB: MDWD (19.7M) vs INMB (50K).
INMBMDWDINMB / MDWD
Capitalization169M220M77%
EBITDA-41.52M-6.58M632%
Gain YTD56.31714.438390%
P/E RatioN/AN/A-
Revenue50K19.7M0%
Total Cash19.3M45.6M42%
Total Debt347K6.46M5%
FUNDAMENTALS RATINGS
INMB vs MDWD: Fundamental Ratings
INMB
MDWD
OUTLOOK RATING
1..100
5223
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
68
Overvalued
PROFIT vs RISK RATING
1..100
8779
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
5442
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDWD's Valuation (68) in the Pharmaceuticals Other industry is in the same range as INMB (92) in the Biotechnology industry. This means that MDWD’s stock grew similarly to INMB’s over the last 12 months.

MDWD's Profit vs Risk Rating (79) in the Pharmaceuticals Other industry is in the same range as INMB (87) in the Biotechnology industry. This means that MDWD’s stock grew similarly to INMB’s over the last 12 months.

MDWD's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as INMB (96) in the Biotechnology industry. This means that MDWD’s stock grew similarly to INMB’s over the last 12 months.

MDWD's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as INMB (54) in the Biotechnology industry. This means that MDWD’s stock grew similarly to INMB’s over the last 12 months.

MDWD's P/E Growth Rating (3) in the Pharmaceuticals Other industry is significantly better than the same rating for INMB (100) in the Biotechnology industry. This means that MDWD’s stock grew significantly faster than INMB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INMBMDWD
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 12 days ago
84%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 24 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
INMB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDWD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DFRSX18.000.23
+1.29%
DFA Asia Pacific Small Company I
EITEX43.350.13
+0.30%
Parametric Tax-Managed Emerg Mkt I
NUIIX31.070.03
+0.10%
Nuveen International Dividend Growth I
CPODX51.04N/A
N/A
Morgan Stanley Insight I
TMPIX54.11N/A
N/A
Touchstone Mid Cap Institutional

MDWD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDWD has been loosely correlated with PHIO. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if MDWD jumps, then PHIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDWD
1D Price
Change %
MDWD100%
+0.15%
PHIO - MDWD
35%
Loosely correlated
-2.23%
AKRO - MDWD
33%
Poorly correlated
-5.33%
KANT - MDWD
30%
Poorly correlated
+8.00%
INMB - MDWD
26%
Poorly correlated
-2.14%
KALA - MDWD
26%
Poorly correlated
+7.16%
More